The combined company starts life with Crestovo’s phase 2 Clostridium difficile candidate and a large-scale stool donation program.

DBV Technologies’ peanut allergy vaccine missed the mark in a phase 3 trial but is still at least 50:50 for FDA approval, say analysts at Jefferies.

MIT scientists have devised a gene circuit that could identify cancer cells more accurately and stimulate the immune system more effectively.

A team of scientists led by the University of Buffalo has developed a vaccine that may guard against 72 strains of the bacterium that causes pneumonia.

Celgene has scrapped a phase 3 trial of inflammatory bowel disease drug GED-0301 after it failed to clear an interim futility review.

The deal gives Roivant, Axovant’s parent company, another part-developed, unloved drug to try to turn into a star.

Gilead boosted oncology chief Riva to EVP, Moderna lost three top R&D officials, Bayer poached Pfizer's consumer marketing vet and more.

Mebias presented rat data showing its mu opioid drugs could become a weapon in the scramble to combat the opioid epidemic.

Johnson & Johnson has notched a deal with Arcturus Therapeutics to help with its new focus on hepatitis B.

Scientists at Max Planck Florida have developed a tool that allows for precise genome editing of neurons.